These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 15217221

  • 1. KIT and PDGF as targets.
    Verweij J.
    Cancer Treat Res; 2004; 120():117-27. PubMed ID: 15217221
    [No Abstract] [Full Text] [Related]

  • 2. Targeting mutant kinases in gastrointestinal stromal tumors: a paradigm for molecular therapy of other sarcomas.
    Heinrich MC, Corless CL.
    Cancer Treat Res; 2004; 120():129-50. PubMed ID: 15217222
    [No Abstract] [Full Text] [Related]

  • 3. [Targeted treatment of cancers with imatinib mesylate (STI571, Gleevec): results of Asco 2002].
    Ray-Coquard I, Blay JY.
    Bull Cancer; 2002 Jun; 89(6):567-9. PubMed ID: 12135855
    [No Abstract] [Full Text] [Related]

  • 4. Immunohistochemical analysis of platelet-derived growth factor receptor-alpha, -beta, c-kit, c-abl, and arg proteins in glioblastoma: possible implications for patient selection for imatinib mesylate therapy.
    Haberler C, Gelpi E, Marosi C, Rössler K, Birner P, Budka H, Hainfellner JA.
    J Neurooncol; 2006 Jan; 76(2):105-9. PubMed ID: 16205964
    [Abstract] [Full Text] [Related]

  • 5. Gastrointestinal stromal tumors: chemotherapy and imatinib.
    Muler JH, Baker L, Zalupski MM.
    Curr Oncol Rep; 2002 Nov; 4(6):499-503. PubMed ID: 12354362
    [Abstract] [Full Text] [Related]

  • 6. Five patients with malignant endocrine tumors treated with imatinib mesylate (Glivec).
    Kindmark H, Janson ET, Gustavsson B, Eriksson C, Larsson G, Granberg D, Kozlowacki G, Skogseid B, Welin S, Oberg K, Eriksson B.
    Acta Oncol; 2010 Nov; 49(1):100-1. PubMed ID: 20100145
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacology of imatinib (STI571).
    Buchdunger E, O'Reilly T, Wood J.
    Eur J Cancer; 2002 Sep; 38 Suppl 5():S28-36. PubMed ID: 12528770
    [Abstract] [Full Text] [Related]

  • 8. The importance of c-Kit and PDGF receptors as potential targets for molecular therapy in breast cancer.
    Roussidis AE, Theocharis AD, Tzanakakis GN, Karamanos NK.
    Curr Med Chem; 2007 Sep; 14(7):735-43. PubMed ID: 17346159
    [Abstract] [Full Text] [Related]

  • 9. [Chemotherapy and target-therapy of gastrointestinal tumors call for development of pathology].
    Shen L.
    Zhonghua Bing Li Xue Za Zhi; 2007 Jul; 36(7):438-9. PubMed ID: 17845753
    [No Abstract] [Full Text] [Related]

  • 10. [Molecular and histologic characteristics of secondary imatinib-resistant gastrointestinal stromal tumors].
    Zheng S, Jia J, Pan YL, Tao DY, Lu HS.
    Zhonghua Bing Li Xue Za Zhi; 2013 Jan; 42(1):42-3. PubMed ID: 23611272
    [No Abstract] [Full Text] [Related]

  • 11. [Effect of STI-571, a c-kit tyrosine kinase inhibitor, in mestastasic gastrointestinal tumor].
    Calvo E, Fernández FJ, Forteza J, Brugarolas A.
    Med Clin (Barc); 2002 Sep 28; 119(10):396-7. PubMed ID: 12372175
    [No Abstract] [Full Text] [Related]

  • 12. Gastrointestinal stromal tumor: involvement in urologic patients and recent therapeutic advances.
    Voelzke BB, Sakamoto K, Hantel A, Paner GP, Kash J, Waters WB, Campbell SC.
    Urology; 2002 Aug 28; 60(2):218-22. PubMed ID: 12137812
    [No Abstract] [Full Text] [Related]

  • 13. Cancer treatment. New drugs, new hope.
    Harv Health Lett; 2001 Jul 28; 26(9):1-3. PubMed ID: 11511447
    [No Abstract] [Full Text] [Related]

  • 14. Multicenter phase II trial assessing effectiveness of imatinib mesylate on relapsed or refractory KIT-positive or PDGFR-positive sarcoma.
    Sugiura H, Fujiwara Y, Ando M, Kawai A, Ogose A, Ozaki T, Yokoyama R, Hiruma T, Ishii T, Morioka H, Mugishima H.
    J Orthop Sci; 2010 Sep 28; 15(5):654-60. PubMed ID: 20953927
    [Abstract] [Full Text] [Related]

  • 15. Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571).
    Demetri GD.
    Eur J Cancer; 2002 Sep 28; 38 Suppl 5():S52-9. PubMed ID: 12528773
    [Abstract] [Full Text] [Related]

  • 16. Imatinib mesylate treatment of recurrent meningiomas in preselected patients: a retrospective analysis.
    Horak P, Wöhrer A, Hassler M, Hainfellner J, Preusser M, Marosi C.
    J Neurooncol; 2012 Sep 28; 109(2):323-30. PubMed ID: 22610940
    [Abstract] [Full Text] [Related]

  • 17. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L.
    Cancer Res; 2005 Mar 01; 65(5):1897-903. PubMed ID: 15753388
    [Abstract] [Full Text] [Related]

  • 18. Moving targets in hepatocellular carcinoma: hepatic progenitor cells as novel targets for tyrosine kinase inhibitors.
    Siegel A.
    Gastroenterology; 2008 Sep 01; 135(3):733-5. PubMed ID: 18692053
    [No Abstract] [Full Text] [Related]

  • 19. Role of KIT and platelet-derived growth factor receptors as oncoproteins.
    Fletcher JA.
    Semin Oncol; 2004 Apr 01; 31(2 Suppl 6):4-11. PubMed ID: 15175998
    [Abstract] [Full Text] [Related]

  • 20. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
    Heinrich MC, McArthur GA, Demetri GD, Joensuu H, Bono P, Herrmann R, Hirte H, Cresta S, Koslin DB, Corless CL, Dirnhofer S, van Oosterom AT, Nikolova Z, Dimitrijevic S, Fletcher JA.
    J Clin Oncol; 2006 Mar 01; 24(7):1195-203. PubMed ID: 16505440
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.